Regulatory FDA approves new high dose Spinraza regimen for SMA PharmaTimesUpdated dosing offers meaningful clinical benefitRegulatoryRare DiseaseRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) PharmaTimes Updated dosing offers meaningful clinical benefit RegulatoryRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Viridian reports positive results from elegrobart phase 3 trialNext: Ambrosia adds a megaround for obesity drugs Related Stories Regulatory Japan approves Sanofi’s Sarclisa combo for MM treatment pharminent June 22, 2026 Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot pharminent June 19, 2026 Regulatory Moderna flu vaccine wins unanimous support from FDA panel pharminent June 18, 2026
